DLA Piper partners Ellen Scordino and Susan Krumplitsch are joined by Duane Valz, General Counsel of Insitro, to discuss how machine learning is being used to generate and leverage data for the development of better medicines.See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.

DLA Piper partners Ellen Scordino and Susan Krumplitsch are joined by Duane Valz, General Counsel of Insitro, to discuss how machine learning is being used to generate and leverage data for the development of better medicines. See omnystudio.com/listener for privacy information.

DLA Piper partners Ellen Scordino and Susan Krumplitsch are joined by Duane Valz, General Counsel of Insitro, to discuss how machine learning is being used to generate and leverage data for the development of better medicines.See <a href="https://omnystudio.com/listener" rel="noopener noreferrer">omnystudio.com/listener</a> for privacy information.

Understanding AI and its use in drug discovery

In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.

Share Understanding AI and its use in drug discovery

Sign up to save your podcasts

Understanding AI and its use in drug discovery

Understanding AI and its use in drug discovery